Navigation Links
ULURU Inc. Presents Results of First Randomized Clinical Trial for Altrazeal(TM) at the Symposium on Advanced Wound Care (SAWC) Fall Meeting in Washington D.C.
Date:9/16/2009

ADDISON, Texas, Sept. 16 /PRNewswire-FirstCall/ -- ULURU Inc. (NYSE Alternext: ULU) announced today the presentation of results from the first completed randomized clinical trial for Altrazeal at the SAWC Fall symposium in Washington D.C. September 16-18. The recently completed clinical study compared healing, pain and comfort of skin graft donor sites treated with either Altrazeal(TM) or with a leading commercial sodium carboxymethylcellulose-silver ("CMC-Ag") dressing.

Major results from the study indicated that there was a significant difference in patient's pain scores, all favoring Altrazeal with lower pain scores at each time point (p<0.0001). When asked about the comfort of the wound dressing at the edges, these subjects found Altrazeal to be more comfortable (p<0.001) and less painful when the dressing came in contact with clothes or bedding (p<0.001). The study endpoints validated the hypothesis for time to healing for both dressings in this particular type of acute surgical wound.

The study was a single-center, prospective randomized trial in which each patient served as his/her own control. Each patient had at least two split-thickness donor sites of which one was dressed with Altrazeal(TM) and the other one with the CMC-Ag dressing.

Renaat Van den Hooff, President and CEO of ULURU Inc., commented: "We are extremely delighted with the results of this clinical trial. Skin graft donor sites are an acute wound that typically heals without any complications, so we expected to show little difference in healing. Nonetheless, these type of surgical wounds are nearly always extremely painful to the patient and to show statistical significance in pain and patient comfort versus a well recognized leading global brand confirms the attributes of Altrazeal(TM) and its promising future."

In addition to the randomized clinical trial, more clinical evidence on the treatment of various wound types using Altrazeal(TM) Transforming Powder Dressing will be presented on multiple posters during the symposium.

About ULURU Inc.:

ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative Nanoflex(TM) Aggregate technology and OraDisc(TM) transmucosal delivery system. For further information about ULURU Inc., please visit our website at www.uluruinc.com. For further information about Altrazeal(TM), please visit www.Altrazeal.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, including but not limited to statements made relating to the benefits, effectiveness, biocompatibility, ease of application, success in wound healing, clinical outcomes, and suitability of Altrazeal(TM), and the success of our clinical efforts. These statements are subject to numerous risks and uncertainties, including but not limited to the risk factors detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2008, and other reports filed by us with the Securities and Exchange Commission.

    Contact: Company
    Renaat Van den Hooff
    President & CEO
    Terry K. Wallberg
    Vice President & CFO
    (214) 905-5145


'/>"/>
SOURCE ULURU Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. ULURU Inc. Reports Second Quarter 2009 Financial Results
2. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Second Quarter Ended June 30, 2009 and to Provide a Business Update
3. ULURU Inc. to Present Altrazeal(TM) Clinical Evidence at the American Podiatric Medical Association (APMA) Annual Scientific Meeting in Toronto, Canada
4. ULURU Inc. Announces Status of York Note Receivable
5. ULURU Inc. Reports First Quarter 2009 Financial Results
6. ULURU Inc. Announces Conference Call to Discuss Financial Results for the First Quarter Ended March 31, 2009 and to Provide a Business Update
7. ULURU Inc. Announces Altrazeal(TM) Clinical Experience Published in the International Wound Journal
8. ULURU Inc. Signs Offer Letter to Acquire York Pharma plc
9. ULURU Inc. (ULURU) Dealing Disclosure Requirements
10. ULURU Inc. Reports Financial Results for Fourth Quarter and Year Ended December 31, 2008
11. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Fourth Quarter and Year Ended December 31, 2008 and to Provide a Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... ... January 18, 2017 , ... ... publication among specialty pharmacists and pharmacy professionals, has teamed up with Ochsner ... (SAP) program, announced Brian Haug, president of Pharmacy Healthcare Communications, LLC, publishers ...
(Date:1/18/2017)... ... January 18, 2017 , ... The Portee Insurance Agency, a family ... owners in central Maryland and the DC region, is inaugurating a charity event aimed ... nationally every year, making it the #1 killer in America. However, heart disease is ...
(Date:1/18/2017)... (PRWEB) , ... January 18, 2017 , ... ... technologies and development solutions for drugs, biologics and consumer health products, today announced ... be presenting at the upcoming WCBP Conference, to be held at the Mayflower ...
(Date:1/18/2017)... ... January 18, 2017 , ... During pregnancy, women are ... erosion, and those dental problems can increase the risk of pregnancy complications. Unfortunately, ... are failing to get the dental care they need. Agoura Hills dentist, Philip ...
(Date:1/17/2017)... York, NY (PRWEB) , ... January 17, 2017 , ... ... grand opening of a new showroom at South Dixie Hwy in Miami, FL. , ... Officer at Gym Source. “The new innovative in-store concept is designed to give clients ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)...  Robust competition in the private marketplace is resulting in ... to a new study by the Berkeley ... to examine the share of prescription medicine spending retained ... health plans and other stakeholders in the supply chain. ... show what happens when the list price of a ...
(Date:1/17/2017)... North America Insulin Delivery Market Outlook to ... Insulin Delivery Market Outlook to 2022", provides key market ... report provides value, in millions of US dollars, volume ... - Insulin Pens, Insulin Pumps, Insulin Syringes and Traditional ... shares and distribution shares data for each of these ...
(Date:1/17/2017)... , Jan 17, 2017 Research and ... Healing Materials: 2017 - 2024" report to their offering. ... This new report ... market report that was issued in May of 2015. Self-healing is ... In our previous analysis we projected a market potential of $2.7 ...
Breaking Medicine Technology: